A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System

Journal of Urban Health

Volumn 92, Issue 4, 2015, Pages 635-649

  Nguyen, John T ^a   Rich, Josiah D ^a,b,c,d   Brockmann, Bradley W ^d   Vohr, Fred ^e   Spaulding, Anne ^f   Montague, Brian T ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c MIRIAM HOSPITAL   (United States)

^d Center for Prisoner Health and Human Rights   (United States)

^e RHODE ISLAND DEPARTMENT OF CORRECTIONS   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

Budget impact analysis; Direct acting antivirals; Hepatitis C; Prisons

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; BUDGET; DRUG COST; ECONOMICS; FEMALE; GOVERNMENT; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; PRISON; PRISONER; RHODE ISLAND; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BUDGETS; DRUG COSTS; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PRISONERS; PRISONS; RHODE ISLAND; STATE GOVERNMENT; YOUNG ADULT;

EID: 84938751142     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-015-9953-4     Document Type: Article

References (53)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011; 31(8): 1090–101. doi:10.1111/j.1478-3231.2011.02494.x.
2. Kim W. The burden of hepatitis C in the United States. Hepatology. 2002; 36(5): S30–4. doi:10.1053/jhep.2002.36791.
3. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010. J Hepatol. 2014; 60(4): 691–8. doi:10.1016/j.jhep.2013.11.014.
4. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013; 368(20): 1859–61. doi:10.1056/NEJMp1302973.
5. Smith BD, Morgan RL, Beckett G, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012; 61: 1–32.
6. Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013; 21(1): 15–9.
7. Bornschlegel K, Holtzman D, Klevens M, Ward JW. Evaluation of hepatitis C virus infection testing and reporting—eight U.S. Sites, 2005–2011. MMWR. 2013; 62(3): 1–5.
8. Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for disease control and prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis. 2012; 55(Suppl 1): S49–53. doi:10.1093/cid/cis363.
9. Mahajan R, Liu SJ, Klevens RM, Holmberg SD. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004–2010. Am J Public Health. 2013; 103(8): 1445–9. doi:10.2105/AJPH.2013.301211.
10. Hunt DR, Saab S. Viral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol. 2009; 104(4): 1024–31. doi:10.1038/ajg.2008.143.
11. Macalino G, Dhawan D, Rich J. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health. 2005; 95(10): 1739–40. doi:10.2105/AJPH.2004.056291.
12. Macalino GE, Vlahov D, Sanford-colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island Prisons. Am J Public Health. 2004; 94(7): 1218–23.
13. McNamara B, Losikoff P, Huguenin L, Macalino GE, Rich JD, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. J Urban. 2013. doi:10.1007/s11524-013-9807-x.
14. Spaulding A, Kim A, Harzke A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med. 2013; 21(1): 27–35. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875217/. Accessed March 16, 2014.
15. Baillargeon J, Snyder N, Soloway RD, et al. Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep. 2009; 124: 120–6.
16. Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013; 58(4): 1215–24. doi:10.1002/hep.26387.
17. Gough E, Kempf M, Graham L, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public. 2010; 10(1): 777. doi:10.1186/1471-2458-10-777.
18. Rhodes AG, Taxman FS, Friedmann PD, Cropsey KL. HCV in incarcerated populations: an analysis of gender and criminality on risk. J Psychoactive Drugs. 2008; 40(4): 493–501. doi:10.1080/02791072.2008.10400655.
19. Martin CK, Hostetter JE, Hagan JJ. New opportunities for the management and therapy of hepatitis C in correctional settings. Am J Public Health. 2010; 100(1): 13–7. doi:10.2105/AJPH.2008.147629.
20. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med (Baltim). 1999; 28(1): 92–100. doi:10.1006/pmed.1998.0418.
21. Estelle v. Gamble, 429 US Supreme Court 97 (1976). Accessed July 15, 2014.
22. Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. N Engl J Med. 2014; 370(20): 1871–4. doi:10.1056/NEJMp1311941.
23. Ghany M, Strader D, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335–74. doi:10.1002/hep.22759.
24. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009; 43(7): 686–91.
25. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003; 138: 187–91.
26. Maru DS-R, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008; 47(7): 952–61. doi:10.1086/591707.
27. Sterling RK, Hofmann CM, Luketic VA. Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004; 99(5): 866–72. doi:10.1111/j.1572-0241.2004.30310.x.
28. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20): 1878–87. doi:10.1056/NEJMoa1214853.
29. Jacobson I, Gordon S, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20): 1867–77. doi:10.1056/NEJMoa1214854.
30. US Department of Health and Human Services. FDA approves Viekira Pak to treat hepatitis C. US Food and Drug Administration. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm. Published December 19, 2014. Accessed February 1, 2015.
31. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594–603. doi:10.1056/NEJMoa1315722.
32. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983–92. doi:10.1056/NEJMoa1402338.
33. Pol S, Vallet-Pichard A, Corouge M. Treatment of hepatitis C virus genotype 3-infection. Liver Int. 2014; 34(Suppl 1): 18–23. doi:10.1111/liv.12405.
34. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3): 211–21. doi:10.1056/NEJMoa1306218.
35. Shiffman ML, Benhamou Y. HCV F1/F2 patients: treat now or continue to wait. Liver Int. 2014; 34(Suppl 1): 79–84. doi:10.1111/liv.12408.
36. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. 2014;59(4):1246–9. doi:10.1002/hep.27039.
37. Japsen B. As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles. Forbes. 2014. http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/. Published October 10 2014. Accessed Novemer 23, 2014.
38. Associated Press. Oregon Medicaid targets expensive hepatitis drug. The Washington Post. 2014. http://www.washingtonpost.com/national/health-science/oregon-medicaid-targets-expensive-hepatitis-drug/2014/07/31/4af1855a-1912-11e4-88f7-96ed767bb747_story.html. Published July 31, 2014. Accessed November 23, 2014.
39. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in u.s. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014; 161(8): 546–53. doi:10.7326/M14-0602.
40. Hammett T. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med. 2003; 138(3): 235–6. Available at: http://annals.org/article.aspx?articleid=716017. Accessed March 15, 2014.
41. Chew K, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavriin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009; 43(7): 686–91. doi:10.1097/MCG.0b013e31818dd94c.
42. Gregory B, Van Horn C, Kaprielian VS. 8 steps to a chart audit for quality. Fam Pract Manag. 2008; 15(7): A3–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18763679. Accessed December 11, 2014.
43. State of Rhode Island and Providence Plantations. Budget Fiscal Year 2014 Volume IV - Public Safety, Natural Resources, and Transportation. http://www.budget.ri.gov/Documents/PriorYearBudgets/OperatingBudget2014/BudgetVolumeIV/2_DepartmentOfCorrections.pdf. Accessed April 15, 2014.
44. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2015; 384(9956): 1756–65. doi:10.1016/S0140-6736(14)61036-9.
45. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N Engl J Med. 2014:1889–1898. doi:10.1056/NEJMoa1402454.
46. Federal Bureau of Prisons. Interim Guidance for the Management of Chronic Hepatitis C Infection. http://www.bop.gov/resources/pdfs/hepatitis_c_current.pdf. Accessed July 15, 2014.
47. Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008; 15(11): 797–808. doi:10.1111/j.1365-2893.2008.01008.x.
48. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013; 56(10): 1382–93. doi:10.1093/cid/cit069.
49. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014; 2015: 1–20. doi:10.1111/apt.13081.
50. Sanger-Katz M. Why the Hepatitis Cure Sovaldi is a Budgetary Disaster for Prisons. New York Times. http://www.nytimes.com/2014/08/07/upshot/why-the-hepatitis-cure-sovaldi-is-a-budgetary-disaster-for-prisons.html?_r=0&abt=0002&abg=1. Published August 7 2014. Accessed November 23, 2014.
51. Klein S, Wright L, Birkhead G, et al. Promoting HCV treatment completion for prison inmates: New York State’s hepatitis C continuity program. Public Health Rep. 2007; 122(2): 83–8.
52. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997; 349(9055): 825–32. doi:10.1016/S0140-6736(96)07642-8.
53. Mauskopf JA, Sullivan SD, Annemans L. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health. 2007; 10(5): 336–47. doi:10.1111/j.1524-4733.2007.00187.x.